Recent investigations have centered on the overlap of GLP|GIP|GCGR activator therapies and dopamine neurotransmission. While GIP agonists are commonly employed for treating type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically governed by dopamine networks, are receiving substantial interest. This report presents